Bloomberg Intelligence cover image

Novo Halves Ozempic Price to $499 a Month For Those Paying Cash

Bloomberg Intelligence

00:00

Price Reduction and Accessibility of Ozempic and Wegovy

This chapter delves into the recent price reduction of Ozempic, bringing it to $499 a month for cash-paying customers, and its implications for patient access and market competition. It also highlights Novo's collaborations with GoodRx and telehealth companies to improve availability for uninsured individuals.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app